FDA Ad Com this week for Epizyme’s tazemetostat for epitheloid sarcoma

The FDA’s Oncologic Drugs Advisory Committee will meet on Wednesday, December 18, to review and discuss Epizyme’s (EPZM +3.6%) marketing application for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

Meeting materials

https://seekingalpha.com/news/3526571-fda-ad-com-this-week-for-epizymes-tazemetostat-for-epitheloid-sarcoma